-
公开(公告)号：EP4356135A1
公开(公告)日：2024-04-24
申请号：EP22735381.0
申请日：2022-06-17
IPC分类号： G01N33/543 , C07K14/00
CPC分类号： G01N33/54353 , G01N2333/24520130101 , C07K14/195 , C07K2319/0020130101 , C07K2319/2120130101
-
公开(公告)号：EP4107182A1
公开(公告)日：2022-12-28
申请号：EP21705555.7
申请日：2021-02-19
申请人： Universiteit Maastricht , F. Hoffmann-La Roche AG , Roche Diagnostics GmbH , Academisch ziekenhuis Maastricht
-
公开(公告)号：EP3017041B1
公开(公告)日：2019-11-06
申请号：EP14735569.7
申请日：2014-07-03
发明人： CZABANY, Tibor , ENGEL, Alfred , GREIF, Michael , JUNG, Christine , LULEY, Christiane , MALIK, Sebastian , MUELLER, Rainer , NIDETZKY, Bernd , RIBITSCH, Doris , SCHMOELZER, Katharina , SCHWAB, Helmut , SOBEK, Harald , SUPPMANN, Bernhard , THOMANN, Marco , ZITZENBACHER, Sabine
IPC分类号： C12N9/10
-
4.发明授权A SOLUBLE COMPLEX COMPRISING A RETROVIRAL SURFACE GLYCOPROTEIN AND FKPA OR SLYD 有权逆转录病毒表面的糖蛋白和OR FkpA的SlyD含有可溶性络合物
公开(公告)号：EP1402015B1
公开(公告)日：2011-08-31
申请号：EP02758265.9
申请日：2002-06-24
IPC分类号： C12N9/90
CPC分类号： G01N33/56988 , A61K39/00 , A61K47/64 , C07K14/005 , C07K2319/00 , C12N9/90 , C12N2740/16122 , G01N33/54306 , G01N33/56911 , G01N33/56983 , G01N2333/005 , G01N2333/16 , G01N2333/195 , G01N2469/20
摘要： The present invention relates to the diagnosis of HIV infections. It especially teaches the production of a soluble retroviral surface glycoprotein- (or transmembrane glycoprotein)- chaperone complex and the advantageous use of a chaperone-antigen complex especially in the detection of antibodies to HIV in immunoassays, preferably according to the double antigen bridge concept, or as an immunogen. The invention also discloses soluble complexes comprising a variant of HIV-1 gp41 or a variant of HIV-2 gp36, respectively, and a chaperone selected from the peptidyl-prolyl-isomerase class of chaperones. Variants comprising specific amino-acid substitutions in the N-helical domain of HIV-1 gp41 or of HIV-2 gp36, respectively are also described.
-
公开(公告)号：EP3781600A1
公开(公告)日：2021-02-24
申请号：EP19715804.1
申请日：2019-04-16
发明人： DUEFEL, Hartmut , ENGEL, Alfred , KRONER, Frank , MEIER, Thomas , RUTZ, Sandra , SCHRAEML, Michael , TABARES, Gloria , KURTKAYA, Ulrike , PINCHUK, Boris , ZIMMERMANN, Christina
IPC分类号： C07K16/40 , G01N33/577
-
公开(公告)号：EP3359966B1
公开(公告)日：2020-01-01
申请号：EP16778831.4
申请日：2016-10-10
-
7.发明公开
公开(公告)号：EP1402015A2
公开(公告)日：2004-03-31
申请号：EP02758265.9
申请日：2002-06-24
IPC分类号： C12N9/90
CPC分类号： G01N33/56988 , A61K39/00 , A61K47/64 , C07K14/005 , C07K2319/00 , C12N9/90 , C12N2740/16122 , G01N33/54306 , G01N33/56911 , G01N33/56983 , G01N2333/005 , G01N2333/16 , G01N2333/195 , G01N2469/20
摘要： The present invention relates to the diagnosis of HIV infections. It especially teaches the production of a soluble retroviral surface glycoprotein- (or transmembrane glycoprotein)- chaperone complex and the advantageous use of a chaperone-antigen complex especially in the detection of antibodies to HIV in immunoassays, preferably according to the double antigen bridge concept, or as an immunogen. The invention also discloses soluble complexes comprising a variant of HIV-1 gp41 or a variant of HIV-2 gp36, respectively, and a chaperone selected from the peptidyl-prolyl-isomerase class of chaperones. Variants comprising specific amino-acid substitutions in the N-helical domain of HIV-1 gp41 or of HIV-2 gp36, respectively are also described.
-
公开(公告)号：EP3017057B1
公开(公告)日：2019-10-02
申请号：EP14736379.0
申请日：2014-07-03
-
公开(公告)号：EP3359966A1
公开(公告)日：2018-08-15
申请号：EP16778831.4
申请日：2016-10-10
发明人： HORSCH, Andrea , KLAPPERICH, Birgit , BLOCK, Dirk , ENGEL, Alfred , KARL, Johann , KIENTSCH-ENGEL, Rosemarie , MANUILOVA, Ekaterina , RABE, Christina , RUTZ, Sandra , SOUKUPOVA, Monika , WIENHUES-THELEN, Ursula-Henrike , KASTNER, Peter , KAISER, Anna Edelgard
摘要： The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.
-
10.发明公开
公开(公告)号：EP3353201A1
公开(公告)日：2018-08-01
申请号：EP16775571.9
申请日：2016-09-22
CPC分类号： C07K16/18 , A61K47/65 , A61K47/6889 , C07K1/1075 , C07K16/00 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/64 , C07K2319/00 , C07K2319/50 , C12N9/52 , C12Y304/2207
摘要： The present disclosure relates to a recombinant immunoglobulin heavy chain comprising a VH-domain a CH1 domain a hinge region down to the C-terminal most cysteine of the middle hinge region, a sortase conjugation loop, a CH2 domain and a CH3 domain, wherein the sortase conjugation loop a) consists of at least 16 amino acids located between the C-terminal most cysteine of the middle hinge region and the VFX1FPP (SEQ ID NO: 2; wherein X1 is L or I) consensus sequence at the N-terminus of an immunoglobulin heavy chain CH2-domain, b) comprises a sortase recognition motif consisting of the amino acid sequence LPX1TX2 (SEQ ID NO: 01), wherein X1 can be any amino acid residue and X2 is G or A, c) comprises N-terminal to the sequence of (b) at least two amino acids, d) comprises C-terminal to the sequence of (b) at least 6 amino acids, and e) wherein the amino acids C- and N-terminal to the sequence of (b) are not cysteine and its use in site-directed conjugation based on the enzyme sortase.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.018 秒)
